Prospective validation of an optimal sparse plasma-sampling strategy for estimating ciprofloxacin pharmacokinetics

Pharmacotherapy

Volumn 16, Issue 5 I, 1996, Pages 937-941

  Amsden, Guy W ^a   Ballow, Charles H ^b,c  

^a BASSETT RESEARCH INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c MILLARD FILLMORE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN;

ADULT; AGED; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CRITICAL ILLNESS; DIAGNOSTIC ACCURACY; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG MONITORING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION;

ADULT; AGED; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; BAYES THEOREM; BIOLOGICAL AVAILABILITY; BLOOD SPECIMEN COLLECTION; CIPROFLOXACIN; CROSS INFECTION; HUMANS; INFUSIONS, INTRAVENOUS; METABOLIC CLEARANCE RATE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES; SKIN DISEASES, INFECTIOUS;

EID: 0029742422     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Drusano GL, Forrest A, Plaisance KI, Standiford HC. Dose ranging and constant infusion evaluation of ciprofloxacin. Antimicrob Agents Chemother 1986;30:440-3.
2. Gonzalez MA, Moranchel AH, Duran S, et al. Multiple dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers. Antimicrob Agents Chemother 1985;28:235-9.
3. Nix DE, Spivey JM, Norman A, Schentag JJ. Dose-ranging pharmacokinetic study of ciprofloxacin after 200, 300, and 400 mg intravenous doses. Ann Pharmacother 1992;26:8-10.
4. Drusano GL, Weir M, Forrest A, Plaisance KI, Emm T, Standiford HC. Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function. Antimicrob Agents Chemother 1987;31: 860-4.
5. Webb DB, Roberts DE, Williams JD, Asscher AW. Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kidney function. J Antimicrob Chemother 1986;18(suppl D):83-7.
6. Fabre D, Bresolle F, Gomeni R, et al. Steady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: penetration of the bronchial mucosa. Antimicrob Agents Chemother 1991;35:2521-5.
7. Forrest A, Ballow CH, Nix DE, Schentag JJ. A new approach for designing population sparse sampling strategies applied to ciprofloxacin pharmacokinetics. Clin Pharmacol Ther 1991;49:153.
8. Forrest A, Ballow CH, Nix DE, Birmingham MC, Schentag JJ. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother 1993;37:1065-72.
9. Guay DRP, Awni WM, Peterson PK, Obaid S, Breitenbucher R, Matzke GR. Pharmacokinetics of ciprofloxacin in acutely ill and convalescent elderly patients. Am J Med 1987;82(suppl 4A):124-9.
10. LeBel M, Bergeron MG, Vallee F, Fiset G, Bigonesse P, Rivard G. Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients. Antimicrob Agents Chemother 1986;30:260-6.
11. Peloquin CA, Cumbo TJ, Nix DE, Sands MF, Schentag JJ. Intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections: impact of plasma concentrations, organism MIC, and clinical condition on bacterial eradication. Arch Intern Med 1989;149:2269-73.
12. Yuen GJ, Drusano GL, Forrest A, Plaisance KI, Caplan ES. Prospective use of optimal sampling theory: steady-state ciprofloxacin pharmacokinetics in critically ill trauma patients. Clin Pharmacol Ther 1989;46:451-7.
13. D'Argenio DZ. Optimal sampling for pharmacokinetic experiments. J Pharmacokinet Biopharm 1981;9:739-56.
14. D'Argenio DZ, Schumitzky A. ADAPT II users guide. Biomedical simulations resource. Los Angeles: University of Southern California, 1992.
15. Drusano GL, Forrest A, Snyder MJ, Reed MD, Blumer JL. An evaluation of optimal sampling strategy and adaptive study design. Clin Pharmacol Ther 1988;44:232-8.
16. Nix DE, DeVito JM, Schentag JJ. Liquid chromatographic determination of ciprofloxacin in serum and urine. Clin Chem 1985;31:684-6.
17. D'Argenio DZ, Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comp Prog Biomed 1979;9:115-34.
18. Sheiner LB, Beal SC. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981;9:503-12.
19. Jelliffe RW, Jelliffe SM. A computer program for estimation of creatinine clearance from unstable serum creatinine levels, age, sex, and weight. Math Biosci 1972;14:17-24.
20. Bauer LA, Piecoro JJ, Wilson HD, Blouin RA. Gentamicin and tobramycin pharmacokinetics in patients with cystic fibrosis. Clin Pharm 1983;2:262-4.
21. Loirat P, Rohan J, Baillet A, Beaufils F, David R, Chapman A. Increased glomerular filtration rate in patients with major burns and its effect on the pharmacokinetics of tobramycin. N EnglJ Med 1978;299:915-19.
22. Zaske DE. Aminoglycosides. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics: principles of therapeutic drug monitoring. Vancouver: Applied Therapeutics, 1992:14-1-14-47.
23. Zaske DE, Cipolle RJ, Strate RJ. Gentamicin dosage requirements: wide interpatient variation in 242 patients with normal renal function. Surgery 1980;87:164.
24. Zaske DE, Cipolle RJ, Strate RJ, Solem LD. Rapid individualization of gentamicin dosage regimens in 66 burn patients. Burns Incl Therm Inj 1981;7:215.